Astria Therapeutics has commenced the Phase Ia clinical trial of monoclonal antibody inhibitor of plasma kallikrein, STAR-0215, to treat hereditary angioedema (HAE).

The randomised, placebo-controlled, double-blind single ascending dose trial has been designed to assess STAR-0215’s pharmacokinetics, pharmacodynamics, and safety in healthy subjects.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

To be conducted at a single centre in the US, the Phase Ia trial will establish clinical proof of concept for the differentiated profile expected for STAR-0215.

In the study, around 24 participants will be given a single STAR-0215 dose or placebo in at least three cohorts of 100mg, 300mg, and 600mg subcutaneously.

It will evaluate the safety and tolerability and has a goal to establish a prolonged half-life and demonstrate inhibition of plasma kallikrein activity.

See Also:

It will also provide proof of mechanism for STAR-0215 as a potential HAE treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Preliminary results from the Phase Ia trial are expected by the end of the year.

Astria Therapeutics chief medical officer Chris Morabito said: “The initiation of the Phase 1a trial of STAR-0215 in healthy subjects is an important milestone for us, as it marks our progression to a clinical-stage company and is a critical next step towards our goal of improving the disease burden for people living with HAE.

“We are proud of our progress so far, and the initiation of our first clinical trial in HAE is a representation of our commitment to bringing hope with life-changing therapies to patients affected by rare diseases.”

STAR-0215 has been designed for providing long-acting, effective attack prevention for HAE.

It demonstrated to be a potent, long-acting, and selective inhibitor of plasma kallikrein, according to preclinical data.